CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study
At 16-months median follow-up, CARVYKTI® significantly improved progression-free survival compared to two standard treatments1 Data presented at the 2023 ASCO and EHA Annual Meetings and published in The New England Journal of Medicine CHICAGO, June 5, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that results from the Phase 3 … [Read more…]